Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT04332588Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluoromisonidazole in breast cancer (2 cohorts), sponsored by University of Alabama at Birmingham. Primary endpoints: Standardized Uptake Value at 6 months, Apparent Diffusion Coefficient at 6 months and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
fluoromisonidazole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04332588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332588.